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adjusted rates (direct method), the overall low back dis-
order rates were compared. Also age, gender, and diagno-
sis-specific low back disorder rates were compared
between two databases.
RESULTS: The overall adjusted prevalence rates of low
back disorders were 1.49 and 1.88 per 100 admissions
for HCUP and MarketScan, respectively. Significant dif-
ference was observed in the age, gender-adjusted rates for
diagnosis of displacement of lumbar intervertebral disc
without myelopathy, with MarketScan showing a higher
rate as compared to HCUP (1.06 vs. 0.781100 admis-
sions). The adjusted average LOS and age, gender, and
diagnosis-specific LOS were higher for HCUP than Mar-
ketScan. The specific and adjusted payments (based on
MarketScan) were, however, higher than the charges re-
ported in HCUP.
CONCLUSIONS: The prevalence rate of low back disor-
ders is higher in the MarketScan database than in HCUP.
The differences in the length of stay and associated costs
might be attributable to other variables such as geograph-
ical variations.
PGD.
OUTCOMES AND COST-BENEFIT OF INHALED
CORTICOSTEROID THERAPY INTRODUCTION
IN MEDICAID·ENROLLED ASTHMATIC
CHILDREN
Balkrishnan R, Norwood GJ
University of North Carolina at Chapel Hill, Chapel Hill,
NC, USA
OBJECTIVE: The purpose of this study was to assess the
clinical and economic impact of the introduction of inhaled
corticosteroid therapy for asthma in a cohort of children 12
years and younger who were North Carolina Medicaid en-
rollees.
METHODS: The North Carolina Medicaid claims data-
base was used to retrieve clinical and economic variables
for the purpose of this study. The case group, which was
comprised of 84 children who started corticosteroid in-
haler therapy between March 1994 and March 1995,
was followed up for 1 year before and 1 year after the
start of the therapy. The control group was comprised of
72 children with similar severity of asthma who remained
on any other therapy other than corticosteroids for a con-
tinuous 2-year period. Paired t-tests were used to com-
pare differences, and multiple regression analysis was
used to adjust for potential confounders.
RESULTS: There was a 58% reduction in hospital visits,
and a 19% reduction in physician visits in the case group
after initiation of inhaled corticosteroids. In the control
group, an increase of 34% in the number of outpatient vis-
its occurred in the second year. All the decreases and in-
creases were statistically significant. Children with regular
patterns of inhaled corticosteroid refills were found to be
significantly lower costing for Medicaid. However, after
adjusting for potential confounders, no significant change
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in health care costs per asthmatic child occurred as a result
of the introduction of inhaled corticosteroid therapy.
CONCLUSION: Overall, the study found that introduc-
tion of inhaled corticosteroids in a cohort of asthmatic
children enrolled in Medicaid was beneficial to Medicaid
because it brought about dramatic decreases in health
care utilization without additionally increasing costs.
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OBJECTIVE: To compare the cost-effectiveness of oral
bambuterol (B) 20 mg once daily with that of salmeterol
(S) pMDI 50 mg twice daily for treatment of asthma pa-
tients with nocturnal symptoms.
METHODS: 126 patients, aged 18-70 years and using
inhaled corticosteroids at a constant daily dose and with
an FEVI 40-85% of predicted normal value, were in-
cluded in this double-blind, randomized, parallel-group
study (2 weeks of run-in and 6 weeks of treatment) in the
UK, Italy, and Norway. During run-in, they had to show
a nocturnal awakening or early awakening due to asthma
symptoms that required rescue medication at least once,
and a 15% fall in overnight PEF on 3 out of the last 7
days. Morning and evening PEF were measured and
tremor was scored. The effectiveness variables in the cost-
effectiveness analysis were symptom-free days and num-
ber of nights with no awakenings. Costs for both study
and rescue medication were calculated.
RESULTS: There were no statistically significant differ-
ences between Band S regarding morning and evening
PEF (change from baseline), tremor, and the effectiveness
variables. Mean number of symptom-free days were 20-
25%, and mean number of nights with no awakenings
were 69-77%. Costs (study + rescue medication) were
lower during bambuterol treatment in all three countries.
UK Italy Norway
Bamb Salm Bamb Salm Bamb Salm
0.71 1.35 0.67 0.92 0.74 1.19
CONCLUSION: Treatment with bambuterol is more
cost-effective than treatment with salmeterol in asthma
patients with nocturnal symptoms.
